Pancreatic Cancer Trial, Recruiting NCT06840067 Sponsor: Gansu Wuwei Tumor Hospital Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT06840067
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 80 years old
  • People who have been diagnosed with locally advanced or spreading (stage III or IV) pancreatic cancer, confirmed through a tissue or cell sample test
  • People who have at least one tumour that can be measured on a scan, according to standard measurement guidelines
  • People who are suitable to receive one cycle of a specific chemotherapy combination (gemcitabine and nituzumab)
  • People who have not had another type of cancer in the past, except for fully cured skin cancer or very early-stage cervical cancer (stage 0)
  • People whose liver, kidney, and blood cell levels are within an acceptable range (confirmed with trial site for specific values)
  • People who are in reasonably good physical health, able to carry out basic daily activities, and have no serious heart or lung conditions that could interfere with radiation treatment
  • People whose major organs are functioning adequately
  • People whose expected survival after treatment is at least 3 months
  • People (or their legal representative) who have signed a consent form before radiation treatment begins

Who may not be able to join:

  • People who have received certain targeted or immune-suppressing treatments (monoclonal antibodies, EGFR-TKI therapy, anti-angiogenic drugs, or immunosuppressants) within the past six months
  • People who have uncontrolled fluid build-up around the lungs, heart, or in the abdomen requiring frequent draining, active gastrointestinal bleeding, or a high bleeding risk in the 14 days before joining
  • People who have taken part in another interventional clinical trial within the past 30 days
  • People whose radiation dose to surrounding healthy organs cannot be kept within safe limits
  • People who have been taking steroid medication long-term (more than 6 months) at doses above a certain level (confirm with trial site for specific dose details)
  • People who are allergic to any of the medications or their ingredients used in this trial
  • People who are pregnant (confirmed by a blood or urine test) or currently breastfeeding
  • People living with HIV/AIDS, including those on antiretroviral therapy, or people with active syphilis
  • People with serious uncontrolled health conditions such as heart, lung, liver, kidney, or blood sugar problems, or those with drug, alcohol, or mental health conditions that could prevent them from completing the trial
  • People who are unlikely to be able to follow the full treatment plan or attend required follow-up appointments
  • People who have or have had another type of cancer (except fully cured skin cancer or very early-stage cervical cancer)
  • People who have any medical reason that makes radiation treatment unsuitable
  • People who do not have the legal capacity to make their own decisions (confirm with trial site)
  • People with any medical history that, in the doctor's judgement, could affect the trial results or raise their risk
  • People whose doctor believes they would not benefit from carbon ion radiation therapy, or where other health factors make participation unsuitable
  • People who do not understand the purpose of the treatment or are unwilling or unable to sign a consent form

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xiaojun Li, Gansu Wuwei Tumor Hospital

Phone: +8613150160200

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Gansu Wuwei Tumor Hospital
Registry
ClinicalTrials.gov
Start date
1 March 2025
Est. completion
31 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov